Affordable Access

deepdyve-link
Publisher Website

Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?

Authors
  • Luo, Wenhao1
  • Yang, Gang1
  • Qiu, Jiangdong1
  • Luan, Jingyang2
  • Zhang, Ying3
  • You, Lei1
  • Feng, Mengyu1
  • Zhao, Fangyu1
  • Liu, Yueze1
  • Cao, Zhe1
  • Zheng, Lianfang4
  • Zhang, Taiping1, 5
  • Zhao, Yupei1
  • 1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. , (China)
  • 2 Department of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, Shanghai, China. , (China)
  • 3 Department of Oncology, The Second Xiangya Hospital, Center South University, Changsha, China. , (China)
  • 4 Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. , (China)
  • 5 Clinical Immunology Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. , (China)
Type
Published Article
Journal
Cancer Medicine
Publisher
Wiley
Publication Date
Oct 01, 2019
Volume
8
Issue
14
Pages
6403–6413
Identifiers
DOI: 10.1002/cam4.2384
PMID: 31475468
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Pancreatic cancer (PC) remains one of the deadliest malignancies worldwide. Chemoresistance is a significant clinical problem in pancreatic ductal adenocarcinoma (PDAC) and numerous potential mechanisms have been demonstrated but much remains to be understood. To overcome the existing limitations in PC treatment, newer approaches targeting intrinsic or acquired mechanisms have been found to improve drug therapeutic effectiveness in PC patients. Here, we provide an update of the most recent findings and their implications for clinicians, and attempt to summarize the various aspects of different individualized novel therapies for PC that could most benefit metastatic PDAC patients. © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times